Filing Flows

Filing Flows › Enanta Pharmaceuticals (ENTA) › Next earnings date

Enanta Pharmaceuticals (ENTA) earnings on Nov 16, 2026: what to expect

Enanta Pharmaceuticals (ENTA) is expected to report earnings on Nov 16, 2026 (estimated), in 8 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.77 (−$0.95 to −$0.55, 5 estimates) on revenue of $15.7M, against −$0.87 and $15.1M a year ago. It beat the EPS estimate in 75% of the quarters on record; Filing Flows' model gives it a 76% chance of beating next time.

Report dateNov 16, 2026 (estimated)
Days to go8
EPS estimate−$0.77
Revenue estimate$15.7M
Beat rate75%

What to watch

Last quarter (Q3 FY26) the lines that make up revenue grew like this; the report shows whether the trend holds:

Enanta Pharmaceuticals: revenue lines, growth year over year, Q3 FY26Enanta Pharmaceuticals: revenue lines, growth year over year, Q3 FY26Revenue-22%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.87 on revenue of $15.0M, against the analysts' −$0.77.

The last report

Enanta Pharmaceuticals reported revenue of $14.4M for the third quarter fiscal 2026 (-22% Y/Y), net loss $19.5M. How it makes money → · Every quarter →

Enanta Pharmaceuticals: EPS against the estimate, last 4 reportsEnanta Pharmaceuticals: EPS against the estimate, last 4 reportsEstimateReported−$1.01−$0.87Nov 25−$0.80−$0.42Feb 26−$0.57−$0.45May 26−$0.54−$0.67Aug 26
Latest (Aug 26): Estimate −$0.54, Reported −$0.67.

Enanta Pharmaceuticals' latest quarter

Enanta Pharmaceuticals, Q3 FY26: revenue $14.4M (-22% year over year), operating margin -120.0%, net loss $19.5M, operating cash flow −$10.0M. The chart follows the revenue to costs, profit and cash.

Questions

When does ENTA report earnings?

Enanta Pharmaceuticals is expected to report on Nov 16, 2026 (estimated).

What are analysts expecting from Enanta Pharmaceuticals?

EPS of −$0.77 and revenue of $15.7M for the quarter.

Does Enanta Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 75% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.